Somaglumetad methionil

Suoyuan biomedical (Hangzhou) Co., Ltd recently announced that its wholly-owned subsidiary, denovo biopharma, has signed an agreement with Lilly to obtain the global rights of the clinical phase III antipsychotic drug pomaglume TAD methionil of Lilly According to the agreement, Suoyuan biomedical will have all rights to develop, produce and sell the medicine globally, including all intellectual property rights and other rights and information Lilly will provide necessary support for Suoyuan and may repurchase the project in the future This has aroused widespread concern in the industry It is reported that pomaglume TAD is the first new drug developed by Lilly for glutamate receptor used in the treatment of schizophrenia, and clinical research has been carried out on its efficacy and safety It has achieved satisfactory results in the phase II clinical trial for schizophrenia, but failed to achieve the expected effect in the subsequent phase III global clinical trial However, further retrospective analysis of multiple clinical trials showed that pomaglume TAD had significant effect on specific subgroups of patients "Lilly is a global R & D-based pharmaceutical company, which is a kind of high-quality late clinical innovative medicine introduced again by Suoyuan biomedical within 6 months, marking another milestone in Suoyuan's development With the introduction of this project, Suoyuan's R & D line has 3 innovative drugs for advanced clinical stage, and the other two new drugs are for lung cancer and lymphoma " "Lilly is a leader in drug research and development in the field of psychiatry As a partner, it will provide valuable help for the follow-up development of somaglume TAD," said Dr Fang Xiangming, chairman of Suoyuan "Compared with the rapid development of personalized medicine in the field of anti-tumor, the development of personalized antipsychotic drugs guided by biomarkers has unique value Because the pathogenesis of psychosis is complex, and the pathogenesis is related to gene inheritance, the advantage of Suoyuan's reverse whole gene scanning platform technology for this kind of disease is more obvious " Dr Luo Wen, general manager of Suoyuan, also said that after years of investment by Lilly, there have been a large number of clinical data about pomaglume TAD Through full gene scanning, Suoyuan will further generate hundreds of millions of data, from which we can dig out gene biomarkers that can predict the efficacy of pomaglume TAD, and hope to make it a new personalized innovative drug for the treatment of mental diseases.